We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
Read MoreHide Full Article
QuidelOrtho Corporation (QDEL - Free Report) recently announced the FDA 510(k) clearance for its QuickVue COVID-19 test.With CLIA certificates of waiver, this approval permits the test to be used accurately and conveniently in home and medical healthcare settings.
The company also provided an update on the Savanna platform that received approval in December 2023.
Price Performance
In the past six months, QDEL’s shares have plunged 43.1% against the industry’s rise of 24.3%. The S&P 500 has gained 19.5% in the same time frame.
Image Source: Zacks Investment Research
More on the News
The QuickVue COVID-19 test was developed for symptomatic individuals within six days of symptom onset. It is approved for use in people aged 14 years and older for self-administration. The test can be administered to people aged two years and older by an adult.
Symptomatic individuals receiving an initial negative result need to undergo e-testing between 48 and 72 hours later with an antigen like QuickVue or a molecular test for SARS-CoV-2. The QuickVue COVID-19 test comes with thorough usage instructions for healthcare providers, making it easy to incorporate into current diagnostic procedures.
Savanna Platform Update
The company received approval for Savanna HSV 1+2/VZV PCR assay in December 2023. This authorization permits U.S. laboratories performing diagnostic testing with moderate to high complexity to market and sell the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV assay.
The company is also developing a Savanna RVP4+ assay intended for use with the Savanna instrument for the simultaneous qualitative detection and differentiation of influenza A (flu A), influenza B (flu B), respiratory syncytial virus (RSV), and SARS-CoV-2 RNA. It had submitted FDA 510(k) submission in July 2023 based on promising initial study data. However, data generated over nine months for the four viruses targeted by the assay failed to meet expectations, which led to the withdrawal of the regulatory submission in February.
Meanwhile, the company continues to develop the next-generation RVP4+ assay, which is expected to be commercially available during the 2024/2025 respiratory season.
The company is also developing a sexually transmitted infection (STI) panel. It is also planning to start a clinical study in the second quarter.
Notable Developments
QuidelOrtho recently announced Health Canada’s approval for its Triage PLGF (placental growth factor) test for laboratory use in Canada. The test is intended to detect the presence of angiogenic imbalance (a consequence of abnormal placentation and poor blood flow in the placenta), which may lead to maternal and fetal complications of pregnancy, including pre-eclampsia.
QDEL carries a Zacks Rank #5 (Strong Sell) at present.
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have surged 51.5% compared with the industry’s 3.6% rise in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
QuidelOrtho's (QDEL) QuickVue Gets FDA Nod for COVID Testing
QuidelOrtho Corporation (QDEL - Free Report) recently announced the FDA 510(k) clearance for its QuickVue COVID-19 test.With CLIA certificates of waiver, this approval permits the test to be used accurately and conveniently in home and medical healthcare settings.
The company also provided an update on the Savanna platform that received approval in December 2023.
Price Performance
In the past six months, QDEL’s shares have plunged 43.1% against the industry’s rise of 24.3%. The S&P 500 has gained 19.5% in the same time frame.
Image Source: Zacks Investment Research
More on the News
The QuickVue COVID-19 test was developed for symptomatic individuals within six days of symptom onset. It is approved for use in people aged 14 years and older for self-administration. The test can be administered to people aged two years and older by an adult.
Symptomatic individuals receiving an initial negative result need to undergo e-testing between 48 and 72 hours later with an antigen like QuickVue or a molecular test for SARS-CoV-2. The QuickVue COVID-19 test comes with thorough usage instructions for healthcare providers, making it easy to incorporate into current diagnostic procedures.
Savanna Platform Update
The company received approval for Savanna HSV 1+2/VZV PCR assay in December 2023. This authorization permits U.S. laboratories performing diagnostic testing with moderate to high complexity to market and sell the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV assay.
The company is also developing a Savanna RVP4+ assay intended for use with the Savanna instrument for the simultaneous qualitative detection and differentiation of influenza A (flu A), influenza B (flu B), respiratory syncytial virus (RSV), and SARS-CoV-2 RNA. It had submitted FDA 510(k) submission in July 2023 based on promising initial study data. However, data generated over nine months for the four viruses targeted by the assay failed to meet expectations, which led to the withdrawal of the regulatory submission in February.
Meanwhile, the company continues to develop the next-generation RVP4+ assay, which is expected to be commercially available during the 2024/2025 respiratory season.
The company is also developing a sexually transmitted infection (STI) panel. It is also planning to start a clinical study in the second quarter.
Notable Developments
QuidelOrtho recently announced Health Canada’s approval for its Triage PLGF (placental growth factor) test for laboratory use in Canada. The test is intended to detect the presence of angiogenic imbalance (a consequence of abnormal placentation and poor blood flow in the placenta), which may lead to maternal and fetal complications of pregnancy, including pre-eclampsia.
QuidelOrtho Corporation Price
QuidelOrtho Corporation price | QuidelOrtho Corporation Quote
Zacks Rank & Stocks to Consider
QDEL carries a Zacks Rank #5 (Strong Sell) at present.
Some better-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Cardinal Health, Inc. (CAH - Free Report) and Cencora, Inc. (COR - Free Report) .
DaVita, sporting a Zacks Rank #1 (Strong Buy), has an estimated long-term growth rate of 12.1%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 35.6%. You can see the complete list of today’s Zacks #1 Rank stocks here.
DaVita’s shares have gained 58.3% compared with the industry’s 18.9% rise in the past year.
Cardinal Health, flaunting a Zacks Rank of 1 at present, has an estimated long-term growth rate of 14.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average being 15.6%.
Cardinal Health has gained 51.9% compared with the industry’s 3.2% rise in the past year.
Cencora, carrying a Zacks Rank of 2 (Buy) at present, has an estimated long-term growth rate of 9.8%. COR’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.7%.
Cencora’s shares have surged 51.5% compared with the industry’s 3.6% rise in the past year.